Zymeworks Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Zymeworks hat ein Gesamteigenkapital von $438.0M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $553.8M bzw. $115.8M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$345.05m
Eigenkapital	US$438.00m
Gesamtverbindlichkeiten	US$115.75m
Gesamtvermögen	US$553.75m

Jüngste Berichte zur Finanzlage

Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

Jun 12

We Think Zymeworks (NYSE:ZYME) Can Afford To Drive Business Growth

Nov 17

Recent updates

Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

Jun 12

Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

May 03

Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind

Jan 31

Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M

Nov 08

Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone

Oct 26

Zymeworks: A Roller Coaster Year

Jul 26

Zymeworks And The Blue Falcon Elucidation

May 17

Zymeworks Inc. (NYSE:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 27

We Think Zymeworks (NYSE:ZYME) Can Afford To Drive Business Growth

Nov 17

Zymeworks: Drop Due To Low Differentiation Against Competition

Jul 05

Zymeworks: Oncology Drug Discovery Company With Major Big Pharma Deals

Dec 11

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: ZYMEDie kurzfristigen Aktiva des Unternehmens ($393.8M) übersteigen seine kurzfristigen Passiva ($56.9M).

Langfristige Verbindlichkeiten: ZYMEDie kurzfristigen Vermögenswerte des Unternehmens ($393.8M) übersteigen seine langfristigen Verbindlichkeiten ($58.9M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: ZYME ist schuldenfrei.

Schulden abbauen: ZYME hatte vor 5 Jahren keine Schulden.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: ZYME auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt.

Vorhersage Cash Runway: ZYME verfügt über eine ausreichende Liquiditätsreserve für 2.5 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 1.2% pro Jahr abnimmt.

Zymeworks Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

We Think Zymeworks (NYSE:ZYME) Can Afford To Drive Business Growth

Recent updates

Zymeworks Inc. Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer

Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

New major risk - Revenue and earnings growth

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data

Zymeworks Inc. to Report Q1, 2024 Results on May 02, 2024

Zymeworks Inc. Removes Dr. Christopher Astle from the Positions of Senior Vice President

Zymeworks Inc. Announces Appointment of Neil Gallagher to Its Board of Directors and as Member of the Research and Development Committee, Effective April 2, 2024

Consensus EPS estimates upgraded to US$0.88 loss, revenue downgraded

New minor risk - Profitability

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Zymeworks Inc. to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting

Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments

High number of new directors

Zymeworks Inc. to Report Q4, 2023 Results on Mar 06, 2024

Zymeworks Announces Appointment of Dr. Alessandra Cesano to Its Board of Directors

Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion

Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind

CEO & Chairman of the Board notifies of intention to sell stock

Investor sentiment improves as stock rises 16%

Zymeworks Inc. Announces Changes to its Board

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zymeworks Inc. to Report Q3, 2023 Results on Nov 07, 2023

Zymeworks Inc., Annual General Meeting, Dec 07, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Zymeworks Inc. Appoints Carlos E. Campoy to the Board of Directors, Effective from June 30, 2023

Jazz Pharmaceuticals plc and Zymeworks Inc. Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Investor sentiment deteriorates as stock falls 16%

Zymeworks Inc. Announces Executive Changes

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 16%

Insufficient new directors

Consensus EPS estimates fall by 10%

Consensus revenue estimates increase by 51%, EPS downgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Price target increased by 8.4% to US$13.73

Consensus revenue estimates increase by 18%

Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Phase 2 Trial Evaluating Zanidatamab in Her2-Expressing Metastatic Gastroesophageal Adenocarcinoma

Consensus revenue estimates increase by 19%

Zymeworks Inc. Removes Neil Josephson from the Position of Chief Medical Officer

Insider recently sold US$8.0m worth of stock

Consensus revenue estimates fall by 12%

Zymeworks Inc. Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab

Consensus revenue estimates fall by 11%

Zymeworks Inc. Announces New Clinical Data for Zanidatamab in Her2+ /Hr+ Metastatic Breast Cancer Presented At 2022 Sabcs

Zymeworks Inc., Annual General Meeting, Dec 16, 2022

Consensus revenue estimates increase by 25%

Price target decreased to US$12.14

Consensus revenue estimates increase by 34%

Third quarter 2022 earnings released: US$0.72 loss per share (vs US$1.17 loss in 3Q 2021)

Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M

Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone

Price target decreased to US$16.35

Consensus revenue estimates increase by 246%

Zymeworks Inc. to Report Q3, 2022 Results on Nov 08, 2022

Price target decreased to US$17.98

Zymeworks Inc. Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) At European Society for Medical Oncology Annual Congress

Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers

Price target decreased to US$21.56

Zymeworks Inc. Appoints Mr. Neil Klompas as President

Zymeworks: A Roller Coaster Year

Zymeworks Inc. to Report Q2, 2022 Results on Aug 04, 2022

Zymeworks Inc. Appoints Dr. Paul Moore as Chief Scientific Officer, Effective July 18, 2022

Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2-Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022

All Blue Falcons FZE cancelled the acquisition of the remaining 94.56% stake in Zymeworks Inc. (NYSE:ZYME).

Zymeworks And The Blue Falcon Elucidation

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$27.55

Alan Barge Would Serve on Zymeworks Inc.'s Board

Insider recently bought US$21m worth of stock